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Introduction
Breast cancer is a heterogeneous disease, composed 
of many morphological and molecular entities. The 
heterogeneity reflects different clinical outcomes (Polyak, 
2007). By gene expression profiling, breast cancer is 
classified into 5 intrinsic subtypes (Perou et al., 2000; 
Sølie et al., 2001). For clinicopathological practice, 5 
molecular subtypes, luminal A, luminal B (HER2-), 
luminal B (HER2+), HER2 and triple negative (TN), are 
defined based on the expression of estrogen receptor (ER), 
progesterone receptor (PgR), human epidermal growth 
factor receptor 2 (HER2), and Ki-67 (Goldhirsch et al., 
2011). TN was subdivided into two subtypes, basal-like 
and null (Nielsen et al., 2004; Chuangsuwanich et al., 
2014). It is well known that molecular subtypes are 
important biological markers not only for predicting 
prognosis but for decisions of effective treatment (Blows et 
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al., 2010; Engstrø et al., 2013; Sung et al., 2016). Luminal 
types are cancers with a better prognosis in comparison to 
non-luminal types. Luminal breast cancer subtypes were 
found to predominate across racial/ethnic groups, while 
frequency of TN breast cancer progressively increases 
among white American, African-American, and Ghanaian/
Africans (Amirikia et al., 2011; Huo et al., 2009; Kurian 
et al., 2010; Stark et al., 2010).
As with other countries, breast cancer is a leading 
cause of morbidity and mortality in Myanmar women 
(Moore, 2014). The aim of this study was to unveil 
the histopathological features and molecular subtypes 
in Myanmar breast cancer patients. We analyzed the 
clinicopathological characteristics and expression patterns 
of ER/PgR/HER2/Ki-67 using 91 female patients with 
breast cancer.
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Materials and Methods
Study subjects
A total of 91 female patients diagnosed with breast 
cancer in the year 2015 were retrieved from pathology 
records at Myeik General Hospital (Myeik City, Myanmar) 
and Sakura Specialist Hospital (Yangon City, Myanmar). 
Clinicopathological data such as age, tumor size, lymph 
node and distant metastasis status were retrieved from 
the clinical and pathology records. All hematoxylin and 
eosin-stained sections were reviewed by two independent 
pathologists. Criteria defined by the World Health 
Organization (2012) were used for the histopathological 
diagnosis and classification of breast carcinoma. 
Nottingham combined histological grading system (Elston 
and Ellis, 1991) was used for tumor grading. American 
Joint Committee on Cancer staging system 8th edition 
was applied for tumor staging. The experimental protocol 
employed in this study was approved by the Ethics 
Committee of Okayama University (Japan) and the Ethics 
Review Committee of Department of Medical Research 
of Yangon City (Myanmar). 
Immunohistochemical analysis
Immunohistochemistry was performed by using 
standardized automated techniques according to the 
manufacturer’s protocol. Tissue sections were stained 
with antibodies ER (SP1), PgR (1E2), HER2 (4B5), Ki-67 
(MIB-1), cytokeratin (CK) 5/6 (D5/16B4) and CK14 
(LL002) using a Discovery XT autostainer with iVIEW 
DAB detection kit (Ventana Medical Systems, Tucson, 
Arizona). In case of ER/PgR, a staining > 1% of tumor 
cell nuclei was considered positive (Hammond et al., 
2010). HER2 was analyzed according to the American 
Society of Clinical Oncology and College of American 
Pathologists (Wolff et al., 2013). A score of 0 to 1+ was 
considered as negative and 3+ as positive. Specimens with 
score of 2+ were analyzed by HER2 dual-color in situ 
hybridization at Hyogo Clinical Laboratory Cooperation 
(Himeji City, Japan). Ki-67 labeling index was defined 
as the percentage of positive nuclei, in which over 500 
tumor cells were counted in each case. CK5/6 and CK14 
were scored positive if any (weak or strong) cytoplasmic 
and/or membranous staining was observed. Breast cancers 
were classified into 5 molecular subtypes according 
to the St. Gallen International Expert Consensus 2011 
(Goldhirsch et al., 2011): luminal A; ER/PgR+/HER2-/
Ki-67<14%, luminal B (HER2-); ER/PgR+/HER2-/Ki-
67≥14%, luminal B (HER2+); ER/PgR+/HER2+/any 
Ki-67 percentage, HER2; ER/PgR-/HER2+, and TN; ER/
PgR-/HER2-. TN subtype was further subdivided into 
basal-like type (ER/PgR-/HER2- with CK5/6+ and/or 
CK14+) and null type (ER/PgR-/HER2-/ CK5/6-/CK14-).
Statistical analysis
Statistical analyses were performed using SPSS 
software version 16.0. Fisher’s exact test was used for 
data categorized into 2 × 2 contingency tables. The age, 
mitosis count and Ki-67 expression were reported using 
descriptive statistics and Mann Whitney U test to compare 
the mean of the variables. Two-sided tests were used for all 
analyses and p value <0.05 was considered as significant.
Results
Patient characteristics
Clinical data for the enrolled 91 female patients with 
breast cancer were shown in Table 1. Ages ranged from 
30 to 81 years with mean age of 51.3. Tumor sizes ranged 
from 1.5 cm to 7.2 cm with average size of 4.0 cm. Most 
of the cancers (94.5%) were invasive carcinoma of no 
special type (NST) with high histological grade (grade II; 
46.2%, grade III; 53.8%). No grade I tumor was found. 
There were lymph node metastases in 57.1% of patients. 
The numbers of patients with stage I, II, III and IV were 6 
(6.6%), 50 (54.9%), 31 (34.1%) and 4 (4.4%), respectively. 
Molecular subtypes and immunophenotypic analyses
ER positive, PgR positive and HER2 positive cases 
were 57.1%, 37.4% and 28.6%, respectively. Molecular 
subtypes and clinicopathological features of 91 breast 
cancers were shown in Table 2. The frequency of luminal 
A, a good prognostic subtype, was 11.0%. The most 
common subtype (39.6%) was luminal B (HER2-). 
Poor-prognosis subtypes, HER2 and TN subtypes, were 
Table 1. Clinical Data for the Enrolled Breast Cancer 
Patients
Categories Number of 
Cases (%)
Age (years)
     <35 4 (4.4)
     35-50 39 (42.9)
     >50 48 (52.7)
Tumor size (cm)
     ≤2.0 6 (6.6)
     2.1-5.0 61 (67.0)
     >5.0 24 (26.4)
Histological type
     Invasive carcinoma of no special type 
(NST)
86 (94.5)
     Mucinous carcinoma 2 (2.2)
     Carcinoma with neuroendocrine 
differentiation
2 (2.2)
     Pleomorphic lobular carcinoma 1 (1.1)
Histological grade
     Grade I 0 (0.0)
     Grade II 42 (46.2)
     Grade III 49 (53.8)
Metastatic lymph node
     Absent 39 (42.9)
     Present 52 (57.1)
Staging
     Stage I 6 (6.6)
     Stage II 50 (54.9)
     Stage III 31 (34.1)
     Stage IV 4 (4.4)
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and the associations between Ki-67 expression and 
clinicopathological features were investigated (Table 3). 
Compared to Ki-67<14 as the reference, tumors with 
increased Ki-67 expression were associated with 
unfavorable features such as more mitoses and higher 
grade. Furthermore, younger patients, larger size (>2 cm), 
and higher stage were related to tumors with >30% Ki-67 
expression. Interestingly, no difference was found in nodal 
status. ER/PgR negative tumors showed higher Ki-67 
expression, whereas Ki-67 expression was not associated 
with HER2 overexpression. Overall, these data indicated 
that Ki-67 expression was significantly accompanied by 
advanced and aggressive cancer.
Discussion
The present study reported the histopathological 
characteristics of Myanmar breast cancer patients. We 
analyzed 91 cases, in which 93% of the breast cancers 
were larger than 2 cm. There was no histological grade I 
and 53.8% of the cancers were grade III. Over half of the 
patients (57.1%) had lymph node involvement at the time 
of diagnosis. These findings may result from the lack of 
early detection system in Myanmar. It is also possible that 
22.0 and 20.9%, respectively. Among TN subtypes, 11 
cases (12.1%) were basal-like type (7 cases; CK5/6+ and 
CK14+, 4 cases; CK5/6- and CK14+) and 8 cases (8.8%) 
were null type. Compared to luminal A as the reference, 
tumors larger than 2 cm were more in HER2 subtype. 
TN-basal-like also tended to be larger than 2 cm although 
it was not statistically significant. Histological grade III 
(poorly differentiated) was more frequently found in 
non-luminal A subtypes, particularly in TN-basal-like and 
HER2, with more advanced stages at diagnosis (stage II, 
III and IV). As compared to luminal A, HER2 subtype 
tended to metastasize to lymph nodes, although it was 
not statistically significant (Table 2). The mean Ki-67 
index of all 91 cases was 33.9% (mean ± SD, 33.9 ± 
19.2) and the median score was 28% (range; 4%-90%). 
In the subtype analyses, the mean Ki-67 expression was 
increased in the following order; luminal A < luminal B 
< HER2 < TN (null<basal-like), which corresponded well 
to the increased number of mitoses (Table 2). 
Assoc ia t ion  be tween  Ki -67  express ion  and 
clinicopathological features
The Ki-67 expression was divided into 3 
levels (<14; 12.1%, 14-30; 40.7%, >30; 47.2%) 
Luminal A Luminal B HER2 Triple Negative Total
HER2- HER2+ basal-like null
Number (%) 10 (11.0) 36 (39.6) 6 (6.6) 20 (22.0) 11 (12.1) 8 (8.8) 91
Age (years)
     Mean (range) 58 (42-81) 52 (32-75) 47 (30-60) 51 (30-74) 49 (35-62) 50 (37-67)
     p value reference 0.158 0.103 0.134 0.121 0.142
Tumor Size
     ≤2cm 3 2 1 0 0 0 6
     >2cm 7 34 5 20 11 8 85
     p value reference 0.061 1 0.030* 0.09 0.216
Histological grade
     Grade II 10 25 1 2 1 3 42
     Grade III 0 11 5 18 10 5 49
     p value reference 0.088 0.001* <0.001* <0.001* 0.007*
Nodal status
     negative 7 15 2 6 7 2 39
     positive 3 21 4 14 4 6 52
     p value reference 0.159 0.302 0.056 1 0.153
Stage
     Stage I 3 2 1 0 0 0 6
     Stage II to IV 7 34 5 20 11 8 85
     p value reference 0.061 1 0.030* 0.09 0.216
Ki-67 expression
     Mean (range) 7 (4-13) 30 (17-80) 30 (9-54) 40 (18-77) 57 (26-90) 43 (20-75)
     p value reference <0.001* 0.003* <0.001* <0.001* <0.001*
Mitoses/10HPF    
     Mean (range) 12 (6-20) 27 (6-86) 39 (21-72) 40 (18-93) 77 (38-118) 49 (18-110)
     p value reference 0.002* 0.001* <0.001* <0.001* 0.001*
Table 2. Molecular Subtypes and Clinicopathological Features of Breast Cancers
*statistically significant
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Myanmar breast cancers are aggressive in nature. 
Revealing the hormonal receptor status and HER2 and 
Ki-67 expression is useful not only for treatment strategy 
but for estimating the patient prognosis (malignant 
potential) (Goldhirsch et al., 2011). Generally, overall 
survival of breast cancers by subtypes from good- to 
poor-prognosis is: luminal A, luminal B, HER2 and TN 
(Hennigs et al., 2016). ER positive breast cancers are 
most frequent in western countries. In the United States, 
most (73%) breast cancers are luminal A and luminal 
B (HER2-) subtypes. About 10% of breast cancers are 
luminal B (HER2+), 4% are HER2 and 12% are TN 
(Howlader et al., 2014). Table 4 shows the summary of 
the percent composition of molecular subtypes of breast 
cancers in western countries, South Asia, South-east Asia 
and East Asia. In Asian countries except China, HER2 and 
TN subtypes are prevailing compared to those in western 
countries. In the present Myanmar study, unfavorable 
molecular subtypes, HER2 and TN, were responsible for 
42.9% of all cancers, suggesting that most breast cancers 
in Myanmar are aggressive in nature. Interestingly, the 
composition of molecular subtypes in Myanmar (this 
study) is comparable to that in a Vietnamese study (Thang 
et al., 2015), with low luminal A and B and in contrast high 
HER2 and TN. These similarities may be related to some 
genetic or biological connections, as well as comparable 
environmental factors.
In conclusion, the present study for the first time 
highlights the clinicopathological features of breast 
cancers from Myanmar women, which provide valuable 
information for the breast cancer control. Approximately 
80% of the breast cancers were positive for either hormone 
receptor or HER2. Hormone therapy and anti-HER2 
therapy may offer significant benefits to the Myanmar 
breast cancer patients, when used properly. Moreover, it 
is essential to establish early detection of breast cancer: 
education to promote early diagnosis and screening. 
Ki-67 index Categories (%) Total
Index <14 14-30 >30
Number (%) 11 (12.1) 37 (40.7) 43 (47.2) 91
Age (years) 
     Mean (range) 57 (42-81) 54 (32-75) 48 (30-75)
     p value reference 0.589 0.037*
Tumor size
     ≤2cm 3 2 1 6
     >2cm 8 35 42 85
     p value reference 0.072 0.023*
Histological grade
     Grade II 10 20 12 42
     Grade III 1 17 31 49
     p value reference 0.035* <0.001*
Nodal Status
     positive 4 22 26 52
      negative 7 15 17 39
     p value reference 0.302 0.186
Stage
     Stage I 3 2 1 6
     Stage II to IV 8 35 42 85
     p value reference 0.072 0.023*
ER
     positive 11 26 15 52
     negative 0 11 28 39
     p value reference 0.048* <0.001*
PgR
     positive 11 15 8 34
     negative 0 22 35 57
     p value reference <0.001* <0.001*
HER2
     positive 1 9 16 26
     negative 10 28 27 65
     p value reference 0.416 0.143
Mitoses/10HPF  
     Mean (range) 14 (6-36) 31 (6-108) 48 (6-118)
     p value reference 0.001* <0.001*
Table 3. Association between Ki-67 Expression and 
Clinicopathological Features  
L
um
inal A
L
um
inal B
 (%
)
H
E
R
2
T
N
N
um
ber of cases
reference
(%
)
H
E
R
2-
H
E
R
2+
(%
)
(%
)
U
nited S
tates
(72.7
)
10.3
4.6
12.2
50,571
H
ow
lader et al., 2014
Italy
34.0
25.0
11.0
10.2
19.0
1,487
C
aldarella et al., 2013
G
erm
any
44.7
31.8
6.2
5.0
12.3
3,454
H
ennigs et al., 2016
A
ustralia
29.0
37.0
14.0
4.6
16.0
285
M
andaliya et al., 2016
India
(53.3
)
10.1
13.0
23.8
1,284
D
oval et al., 2015
C
hina
(65.3
)
19.0
6.5
9.2
3,198
Z
hu et al., 2014
Japan
30.6
26.2
19.0
11.3
12.9
363
Y
anagaw
a et al., 2012
Indonesia
38.1
(16.7
)
20.2
25.0
84
W
idodo et al., 2014
M
alaysia
(48.0
)
12.0
11.0
29.0
1,034
D
evi et al., 2012
Thailand
39.0
8.0
10.0
18.0
25.0
100
C
huangsuw
anich et al., 2014
V
ietnam
10.6
33.5
23.0
19.3
13.6
237
T
hang et al., 2015
M
yanm
ar
11.0
39.6
6.6
22.0
20.9
91
P
resent study
Table 4. P
ercent C
om
position of M
olecular S
ubtypes of B
reast C
ancer in D
ifferent C
ountries
Asian Pacific Journal of Cancer Prevention, Vol 18 1621
DOI:10.22034/APJCP.2017.18.6.1617
Breast Cancer Molecular Subtypes in Myanmar
 
Early detection alleviates the advanced breast cancer and 
increases the opportunities for successful treatment.
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